• admin
• December 18, 2025

Objective

To assess the cost-effectiveness of treatments for locally advanced and metastatic cancer

Methods

• Developed a cohort partitioned survival model informed by published clinical trial data
• Digitised Kaplan–Meier survival curves to reconstruct patient-level data and fitted appropriate parametric survival distributions
• Applied treatment-specific hazard ratios to estimate progression-free survival (PFS) and overall survival (OS)
• Incorporated treatment, disease management, and end-of-life costs, along with health-state utility values, into the model

Outcome

The model generated estimates of total costs, QALYs, and incremental cost-effectiveness, providing decision-grade evidence to support decision-making